Dupilumab-induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin-17A expression: a case report

Br J Dermatol. 2021 Aug;185(2):432-434. doi: 10.1111/bjd.20064. Epub 2021 May 4.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Dermatitis, Atopic* / chemically induced
  • Dermatitis, Atopic* / drug therapy
  • Humans
  • Interleukin-17
  • Phenotype
  • Psoriasis* / chemically induced
  • Psoriasis* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • Interleukin-17
  • dupilumab